Marinus Pharmaceuticals (NASDAQ:MRNS) Cut to “Sell” at StockNews.com

StockNews.com downgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a hold rating to a sell rating in a research note issued to investors on Thursday morning.

Several other research firms have also commented on MRNS. Oppenheimer upgraded shares of Marinus Pharmaceuticals from a market perform rating to an outperform rating and set a $6.00 price objective on the stock in a research report on Monday, September 23rd. Cantor Fitzgerald restated an overweight rating and issued a $13.00 target price on shares of Marinus Pharmaceuticals in a report on Tuesday, September 24th. HC Wainwright restated a buy rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. LADENBURG THALM/SH SH lowered shares of Marinus Pharmaceuticals from a buy rating to a neutral rating in a report on Wednesday, August 14th. Finally, Truist Financial restated a buy rating and issued a $10.00 target price on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Marinus Pharmaceuticals currently has an average rating of Hold and a consensus price target of $8.83.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ MRNS opened at $1.84 on Thursday. The firm has a market capitalization of $101.08 million, a P/E ratio of -0.70 and a beta of 1.13. Marinus Pharmaceuticals has a one year low of $1.05 and a one year high of $11.26. The company’s fifty day moving average is $1.41 and its two-hundred day moving average is $2.62. The company has a debt-to-equity ratio of 5.68, a quick ratio of 2.15 and a current ratio of 2.28.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. The business had revenue of $8.06 million during the quarter, compared to analysts’ expectations of $9.05 million. During the same quarter in the prior year, the firm earned ($0.61) earnings per share. Analysts forecast that Marinus Pharmaceuticals will post -1.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP increased its stake in shares of Marinus Pharmaceuticals by 54.8% during the 4th quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock valued at $2,623,000 after acquiring an additional 85,455 shares during the last quarter. Vanguard Group Inc. increased its position in Marinus Pharmaceuticals by 5.0% during the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after purchasing an additional 132,689 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Marinus Pharmaceuticals during the 2nd quarter worth approximately $813,000. Hussman Strategic Advisors Inc. increased its position in Marinus Pharmaceuticals by 14.3% during the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 10,500 shares in the last quarter. Finally, Trexquant Investment LP acquired a new stake in Marinus Pharmaceuticals during the 4th quarter worth approximately $553,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.